Haematobiochemical and Histopathological Studies on the Effects of Raj Nirwan Bati (a Novel Allovedic Drug) in Wistar Rats

Abstract

Abstract: Raj Nirwan Bati (RNB) world’s first “ALLOVEDIC” medicine, that has been formulated at UP University of Medical Sciences, Saifai, Etawah and scientifically proven to be effective in the treatment of COVID-19, can prove to be a milestone in containing this pandemic in India as well as rest of the world. This study was conducted to see the effects of Raj Nirvan Bati (RNB) on haematobiochemical parameters and histopathological changes in the lungs, liver and kidneys and also to evaluate the immunomodulatory activity of RNB in wistar rats. In this study a total of 24 adult albino Wistar rats (approx.200-250 gms.) of either sex were used to study the effects of RNB on haematobiochemical parameters and histology of organs. Rats were procured from the Animal Husbandry department of UP University of Medical Sciences (UPUMS), Saifai, Etawah. The rats were weighed, marked and divided into 3 groups each consisting of 8 animals. In normal control group (n=8), no drug was administered and in rest of the groups (A & B), Raj Nirwan Bati @ 26 mg/kg B.wt./day and 260 mg/kg B.wt./day respectively was administered orally for a period of 14 days. The blood samples were collected from jugular vein at zero day (before drug administration) and after 14th day of drug administration in both groups (A and B) after giving light anaesthesia with Ketamine injection IM. The organ samples (Lungs, Liver, Kidneys and Spleen) were collected after euthanizing the rats by administration of Ketamine anaesthesia overdose IP after 14th day of drug administration. The individual organ index (spleen index) was calculated. After analyzing the results, it was concluded that RNB is having immunomodulatory effect which is indicated by increased percentage of monocytes in both groups A & B after RNB intervention, indicating more number of macrophages and increased phagocytic activity. The results of coagulation tests indicate that the drug RNB might be helpful in restoration of coagulation factors and can be helpful in treating the COVID patients. The therapeutic dose of RNB (26 mg/kg body weight) for a period of 14 days showed no harmful effect on lungs, liver, kidney and spleen with similar histological picture just like control group, however after administration of ten times higher dose of RNB (260 mg/kg body weight) for a period of 14 days, kidney and spleen showed no significant changes while it promotes inflammation and oxidative stress in liver and lungs tissue. The findings of this experimental study of RNB on wistar rats may act as a baseline data for planning further clinical trials in human study subjects to evaluate the effects on various comorbidities.Funding Information: This study was done under intramural research project and its funding source was UP University of Medical Sciences, Saifai, Etawah, U.P., India. Declaration of Interests: No conflicts of interest.Ethics Approval Statement: Approval from Institutional Animal Ethics Committee (IAEC protocol approval no.-IAEC/02/AH/2019-20 dated 07/03/2020) of UPUMS.